Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAVA-1207 in therapy-refractory metastatic castration-resistant prostate cancer
NL-OMON59451Phase 2Completed
- Sponsor
- LAVA Therapeutics
- Start
- Nov 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of LAVA-1207 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by LAVA Therapeutics. Primary endpoints: Frequency and severity of adverse events and Dose-limiting toxicities. Started Nov 2021; status: completed.
02
Drugs
LAVA-1207
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON59451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59451.